Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine

NCT06721494 is registered in ClinicalTrials.gov with Clear Scientific, Inc. as lead sponsor.

NCT NCT06721494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06721494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine
Lead sponsor
Clear Scientific, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
February 5, 2026
Completion date
September 11, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

methamphetamine abuse, methamphetamine disorders, methamphetamine intoxication